We’re committed to meaningfully integrating sustainability considerations into our business practices and culture.
Clinical research and development is complex. Finding the right partner shouldn’t be.
The work we do has a global impact, and we are committed to making it a positive one. Our corporate sustainability practice enables us to engage meaningfully with stakeholders, empower our team members, reduce our environmental impact, and evolve our business model through innovation.
2019 Sustainability Report
PRA’s 2019 Corporate Sustainability report comes at an unprecedented time. Today, our world looks very different than it did when we began compiling…
Sustainable goals for a sustainable future.
We support the United Nations’ 17 Sustainable Development Goals, and our corporate goals align with three in particular:
- Health and Well-Being
- Gender Equality
- Industry Innovation and Infrastructure
We are also an IMPACT 2030 partner. IMPACT 2030 is a private sector, partnership-led initiative to achieve the UN’s goals. By working together, we believe we can make our world a healthier, more prosperous, and peaceful place.Read more about our partnership with IMPACT2030
PRA Talks COVID-19 Impact on Rare Disease Clinical Trials with Patient Advocates
PRA’s Center for Rare Diseases understands that clinical trials are both a source of hope and care for people affected by a rare disease. The impact…
Center for Rare Diseases continues to engage with rare disease patient communities during COVID-19 crisis
PRA Health Sciences’ Center for Rare Diseases is committed to engaging rare disease patient communities, and providing transparency, throughout the…
Ask the Experts: Why Do Rare Disease Clinical Trials Require a Unique Approach?
According to the National Organization for Rare Disorders (NORD), 90% of rare disorders do not have an FDA-approved treatment. We spoke with Juliane…